Results 61 to 70 of about 46,383 (210)
New Zealand Journal of Botany, Volume 64, Issue 1, March 2026.SARS‐CoV2 Omicron and its substrains are still a critical global health issue and extremely contagious, even with widespread vaccination efforts. Hospitalizations and mortality rates linked to these variants are still prevalent. Current therapeutic options face challenges, including low effectiveness, suboptimal pharmacokinetics, and drug resistance ...
Frank Eric Tatsing Foka +1 more
wiley +1 more source
Immunity, Inflammation and Disease, 2023 Background The current absence of gold‐standard or all‐aspect favorable therapies for COVID‐19 renders a focus on multipotential drugs proposed to prevent or treat this infection or ameliorate its signs and symptoms vitally important.
Najmolsadat Atefi +9 more
doaj +1 more source
Reviews in Medical Virology, Volume 36, Issue 2, March 2026.ABSTRACT Small randomized controlled trials (RCTs) in COVID‐19 meta‐analyses have been associated with more favourable treatment effects and reduced result stability. This study assessed how trial size impacts effect estimates, statistical stability, and risk of bias.
Dong Hyun Kim +11 more
wiley +1 more source
Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19)
Journal of Pure and Applied Microbiology, 2020 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached global epidemic status claiming more than 319K lives and affecting more than 4.81M people and counting worldwide.
Abhi Bhadra +6 more
doaj +1 more source
ChemistrySelect, Volume 11, Issue 9, 5 March 2026.ABSTRACT Monkeypox is a reemerging zoonotic disease that has been spreading worldwide. Different approaches are being conducted to find effective treatments for this disease. To accelerate therapeutic discovery, we propose telomere‐binding protein (TBP) as a potential drug target because of its important role during virus maturation.
Edinson Gervacio‐Villarreal +12 more
wiley +1 more source
Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. [PDF]
, 2010 Despite the enormous progress made in scaling up antiretroviral therapy (ART) in sub-Saharan Africa, many challenges remain, not least of which are the identification and management of patients who have failed first-line therapy. Less than 3% of patients
Akileswaran +57 more
core +2 more sources
Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.ABSTRACT Background Viral‐respiratory infections are the most prevalent illness among humans. A viral infection affecting lower respiratory tract infections (LRTI) is a critical health concern worldwide. The COVID‐19 pandemic has significantly impacted respiratory health, particularly in individuals with asthma.
Mandana Akhavan +2 more
wiley +1 more source
Медицинский вестник Юга России, 2018 Objective: to characterize the efcacy of nelfnavir and lopinavir/ritonavir in the starting regimens of antiretroviral therapy for HIV-infected pediatric patients.Materials and methods: 50 HIV-infected patients aged 24-36 months were treated with abacavir
V. B. Denisenko,, E. N. Simovanyan
doaj +1 more source
Pharmaceutical Sciences and Research, 2020 Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be aggravated by comorbid diseases.
Ana Khusnul Faizah +2 more
doaj +1 more source
Preferred antiretroviral drugs for the next decade of scale up [PDF]
, 2012 Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission.
Andrieux-Meyer, Isabelle +10 more
core +4 more sources